Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines

References

• Murawski N, Pfreundschuh. New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol 2010;11:1074–1085.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, . WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
   Google Scholar
• Coiffier B, Lepage E, Briere J, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–342.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Truemper L, Osterborg A, .; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab compared with CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the Mabthera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Salit RB, Bishop MR, Pavletic SZ. Allogeneic hematopoietic stem cell transplantation: does it have a place in treating Hodgkin lymphoma? Curr Hematol Malig Rep 2010;5:229–238.
   PubMedGoogle Scholar
• Srivastava S, Jones D, Wood LL, . A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2011;17:987–994.
   PubMed Web of Science ®Google Scholar
• Suyani E, Sucak GT, Aki SZ, . Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol 2011;90:685–691.
   PubMed Web of Science ®Google Scholar
• Russell JA, Tran HT, Quinlan D, . Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002;8:468–476.
   PubMed Web of Science ®Google Scholar
• de Lima M, Couriel D, Thall PF, . Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004;104:857–864.
   PubMed Web of Science ®Google Scholar
• Andersson BS, de Lima M, Thall PF, . Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008;14:672–684.
   PubMed Web of Science ®Google Scholar
• Andersson BS, Valdez BC, de Lima M, . Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 2011;17:893–900.
   PubMed Web of Science ®Google Scholar
• Farag SS, Wood LL, Schwartz JE, . Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia. Leukemia 2011;25:599–605.
   PubMed Web of Science ®Google Scholar
• Valdez BC, Li Y, Murray D, . The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. Biochem Pharmacol 2011;81:222–232.
   PubMed Web of Science ®Google Scholar
• Plunkett W, Gandhi V. Purine and pyrimidine nucleoside analogs. Cancer Chemother Biol Response Modif 2001;19:21–45.
   PubMedGoogle Scholar
• Valdez BC, Andersson BS. Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies. Environ Mol Mutagen 2010;51:659–668.
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63.
   PubMed Web of Science ®Google Scholar
• Kastan MB, Lim DS. The many substrates and functions of ATM. Nat Rev Mol Cell Biol 2000;1:179–186.
   PubMed Web of Science ®Google Scholar
• Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408:433–439.
   PubMed Web of Science ®Google Scholar
• Kim S-T, Xu B, Kastan MB. Involvement of the cohesion protein, Smc1, in Atm-dependent and independent responses to DNA damage. Genes Dev 2002;16:560–570.
   PubMed Web of Science ®Google Scholar
• Ziv Y, Bielopolski D, Galanty Y, . Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM- and KAP-1 dependent pathway. Nat Cell Biol 2006;8:870–876.
   PubMed Web of Science ®Google Scholar
• Rogakou EP, Pilch DR, Orr AH, . DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858–5868.
   PubMed Web of Science ®Google Scholar
• Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol 2009;21:245–255.
   PubMed Web of Science ®Google Scholar
• Hirano T. SMC-mediated chromosome mechanics: a conserved scheme from bacteria to vertebrates? Genes Dev 1999;13:11–19.
   PubMed Web of Science ®Google Scholar
• Stursberg S, Riwar B, Jessberger R. Cloning and characterization of mammalian SMC1 and SMC3 genes and proteins, components of the DNA recombination complexes RC-1. Gene 1999;228:1–12.
   PubMed Web of Science ®Google Scholar
• Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 2008;9:616–627.
   PubMed Web of Science ®Google Scholar
• Gaidano G, Ballerini P, Gong JZ, . p53 mutations in human lymphoid malignancies - association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991;88:5413–5417.
   PubMed Web of Science ®Google Scholar
• Johnstone RW, Wei W, Greenway A, . Functional interaction between p53 and the interferon-inducible nucleoprotein IFI 16. Oncogene 2000;19:6033–6042.
   PubMed Web of Science ®Google Scholar
• Liu G, Lozano G. p21 stability: linking chaperones to a cell cycle checkpoint. Cancer Cell 2005;7:113–114.
   PubMed Web of Science ®Google Scholar
• Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009;9:400–414.
   PubMed Web of Science ®Google Scholar
• Grandori C, Cowley SM, James LP, . The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000;16:653–699.
   PubMed Web of Science ®Google Scholar
• Varier RA, Timmers HT. Histone lysine methylation and demethylation pathways in cancer. Biochim Biophys Acta 2010;1815:75–89.
   PubMed Web of Science ®Google Scholar
• Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541–5552.
   PubMed Web of Science ®Google Scholar
• Scognamiglio A, Nebbioso A, Manzo F, . HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. Biochim Biophys Acta 2008;1783:2030–2038.
   Google Scholar
• Vaute O, Nicolas E, Vandel L, . Functional and physical interaction between the histone methyl transferase Suv39H1 and histone deacetylases. Nucleic Acids Res 2002;30:475–481.
   PubMed Web of Science ®Google Scholar
• Marchi E, Alinari L, Tani M, . Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005;104:2437–2441.
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Wen S, . Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2006;7:51–58.
   PubMedGoogle Scholar
• Zinzani PL, Venturini F, Stefoni V, . Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 2010;21:860–863.
   PubMed Web of Science ®Google Scholar
• Aribi M, Mesli N, Remla N, . Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients: a prospective randomized trial in Algeria. J Cancer Res Ther 2010;6:41–46.
   PubMed Web of Science ®Google Scholar
• Nieto Y, Anderlini P, Popat U, . Gemcitabine, busulfan and melphalan (GemBuMel) is a new high-dose chemotherapy (HDC) regimen with high activity in refractory Hodgkin's lymphoma (HL) patients receiving an autologous stem-cell transplant (ASCT): a contemporaneous comparison with BEAM and busulfan/melphalan (BuMel). Blood 2010;116(Suppl. 1): Abstract 690.
   Google Scholar
• Younes A. Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol 2011;8:85–96.
   PubMed Web of Science ®Google Scholar
• Smith J, Tho LM, Xu N, . The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010;108:73–112.
   PubMed Web of Science ®Google Scholar
• Wang GG, Allis CD, Chi P. Chromatin remodeling and cancer, part I: covalent histone modifications. Trends Mol Med 2007;13:363–372.
   PubMed Web of Science ®Google Scholar
• van Attikum H, Gasser SM. Crosstalk between histone modifications during the DNA damage response. Trends Cell Biol 2009;19:207–217.
   PubMed Web of Science ®Google Scholar